Immune-related adverse events of immune checkpoint inhibitors: a review

  • Front Immunol. 2023 May 25:14:1167975. doi: 10.3389/fimmu.2023.1167975.
Qinan Yin  1  2 ,  Liuyun Wu  1  2 ,  Lizhu Han  1  2 ,  Xingyue Zheng  1  2 ,  Rongsheng Tong  1  2 ,  Lian Li  1  2 ,  Lan Bai  1  2 ,  Yuan Bian  1  2
Affiliations
  • 1. Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
  • 2. Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
PMID: 37304306 DOI: 10.3389/fimmu.2023.1167975
Abstract

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved. Despite the success of immune checkpoint inhibitors, resistance limits the number of patients who can achieve a lasting response, and immune-related adverse events complicate treatment. The mechanism of immune-related adverse events (irAEs) is unclear. We summarize and discuss the mechanisms of action of immune checkpoint inhibitors, the different types of immune-related adverse events and their possible mechanisms, and describe possible strategies and targets for prevention and therapeutic interventions to mitigate them.

Keywords
epidemiology; immune checkpoint inhibitors; immune-related adverse events; management; mechanism.